Daily Roundup

CXZ.ASX HCW.ASX EPX.ASX COH.ASX AMC.ASX

Strong Results for Connexion Mobility Ltd in FY25

Connexion Mobility Ltd reported a solid financial performance in the 2025 fiscal year, with revenues from ordinary activities increasing by 14% to $11.2 million and net profit before tax rising by 19% to $3.2 million. The company also saw a 19% growth in consolidated net assets, reaching $7.5 million.

Connexion Mobility continued to provide its Software as a Service (SaaS) solutions, the OnTRAC and Connexion platforms, to various automotive original equipment manufacturers (OEMs) in the US. The company's strategy of building economic value through its 'Embed, Integrate, Generate' operating model, as well as creating strategic value by commercializing its OEM and Dealership Networks, has been paying off.

Operationally, Connexion Mobility achieved significant team expansion, feature enhancements to its core platforms, and improvements to the user experience of the Connexion Marketplace. The company also executed a commercial partnership for digital license and insurance verification.

Overall, Connexion Mobility delivered sound operating profitability throughout the period, with the company's net profit before tax increasing from $2.7 million in the prior year to $3.2 million in FY25.

HealthCo REIT Reports FY25 Results Amid Healthscope Situation

HealthCo Healthcare & Wellness REIT (ASX: HCW) has released its results for the year ended 30 June 2025, highlighting a strong financial and operational performance despite the ongoing Healthscope situation.

The REIT reported FY25 funds from operations (FFO) of 6.6 cents per unit (cpu), or $36.5 million, and distributions per unit (DPU) of 4.2 cents. The portfolio maintained a high 98% contracted cash rent collection and 99% occupancy, with a 5.2% like-for-like net operating income growth.

Regarding the Healthscope situation, all 11 hospitals owned by HCW and the Unlisted Healthcare Fund (UHF) continue to operate as normal, with Healthscope paying 100% of contracted rent. HCW and UHF are working proactively with the Receiver on the current Healthscope sale process to replace Healthscope as the tenant across the portfolio.

HCW's balance sheet remains strong, with pro-forma cash and undrawn debt of $103.8 million and a pro-forma gearing of 31%. The company is focused on resolving the Healthscope situation while the remainder of the portfolio continues to perform well.

EPX Receives $2 Million Placement from Institutional Investors

EPX Limited (ASX: EPX) has received commitments from existing institutional shareholders to raise $2 million through a placement of new fully paid ordinary shares. The issue price of $0.022 per share represents a 22% discount to the 20-day volume-weighted average price.

The proceeds from the placement will be used to assist in advancing sales growth, assess further merger and acquisition opportunities, and invest in operational improvements, particularly in aligning EPX's technology with its product roadmap following the acquisition of the Coda Cloud technology.

EPX has also implemented changes to its sales and operational structures, which are driving new sales opportunities. These changes include the release of a new brand and tradename, the creation of a Customer Success team in each market, the expansion of the sales team, and preparation to launch EDGE Industrial in the Asia-Pacific region.

The commitment from institutional shareholders is contingent on EPX meeting its continuous disclosure requirements and providing a cleansing notice. The placement will result in the issue of 90,909,091 new shares, which will be issued under the company's existing capacity.

Cochlear Ltd Reports Strong FY25 Results, Provides FY26 Guidance

Cochlear Ltd, a leading global provider of implantable hearing solutions, has reported its FY25 results, with sales revenue increasing 4% to $2,356 million and statutory net profit up 9% to $389 million.

The company's underlying net profit increased 1% to $392 million, with strong growth in cochlear and acoustic implants partially offset by a decline in Services revenue. Cochlear continued to invest in research and development, with a focus on improving hearing outcomes for recipients through innovations such as drug-eluting electrodes.

Looking ahead, Cochlear provided FY26 underlying net profit guidance of $435-460 million, an 11-17% increase on FY25. The company also announced a 5% increase in the dividend, with a final dividend of $2.15 per share and an interim dividend of $2.15 per share, totaling $4.30 per share for the year.

Cochlear also extended its existing on-market share buyback program, with the buy-back period now extended to 28 August 2026. The company will continue to buy back up to $75 million of its shares as part of the extended program.

Amcor Reports Strong Q4 and FY25 Results, Expects Continued Growth in FY26

Amcor Plc reported strong financial results for the fourth quarter and fiscal year ended June 30, 2025, with the completion of the all-stock acquisition of Berry Global transforming the company's capabilities.

In the fourth quarter, Amcor reported net sales of $5,082 million, up 43% excluding currency impact, and adjusted EBITDA of $789 million, up 43% excluding currency impact. For the full fiscal year, the company reported net sales of $15,009 million, up 11% excluding currency impact, and adjusted EBIT of $1,723 million, up 12% excluding currency impact.

Looking ahead, Amcor expects to deliver strong adjusted EPS growth of 12-17% and a significant increase in free cash flow to $1.8 to $1.9 billion in fiscal 2026. The company has also identified its $20 billion core portfolio of consumer packaging and dispensing solutions for nutrition and health, and outlined optimization actions to further sharpen its focus on attractive categories and drive faster growth.